LinkedIn

 آمار

تعداد نشریات20
تعداد شماره‌ها1,113
تعداد مقالات10,208
تعداد مشاهده مقاله40,780,181
تعداد دریافت فایل اصل مقاله8,803,953
Kiani, Amin, Ghorbani Aliabadi, Elham, Kermani, Bahareh, Rezabeigi Davarani, Fatemeh, Rahmanian, Vahid, Daneshi, Salman. (1403). Assessing the Success and Effectiveness of the Major β-Thalassemia Screening Program in Southeast Iran: A Case Study of Jiroft District. سامانه مدیریت نشریات علمی, 12(3), 319-326. doi: 10.30476/jhsss.2023.97455.1707
Amin Kiani; Elham Ghorbani Aliabadi; Bahareh Kermani; Fatemeh Rezabeigi Davarani; Vahid Rahmanian; Salman Daneshi. "Assessing the Success and Effectiveness of the Major β-Thalassemia Screening Program in Southeast Iran: A Case Study of Jiroft District". سامانه مدیریت نشریات علمی, 12, 3, 1403, 319-326. doi: 10.30476/jhsss.2023.97455.1707
Kiani, Amin, Ghorbani Aliabadi, Elham, Kermani, Bahareh, Rezabeigi Davarani, Fatemeh, Rahmanian, Vahid, Daneshi, Salman. (1403). 'Assessing the Success and Effectiveness of the Major β-Thalassemia Screening Program in Southeast Iran: A Case Study of Jiroft District', سامانه مدیریت نشریات علمی, 12(3), pp. 319-326. doi: 10.30476/jhsss.2023.97455.1707
Kiani, Amin, Ghorbani Aliabadi, Elham, Kermani, Bahareh, Rezabeigi Davarani, Fatemeh, Rahmanian, Vahid, Daneshi, Salman. Assessing the Success and Effectiveness of the Major β-Thalassemia Screening Program in Southeast Iran: A Case Study of Jiroft District. سامانه مدیریت نشریات علمی, 1403; 12(3): 319-326. doi: 10.30476/jhsss.2023.97455.1707

Assessing the Success and Effectiveness of the Major β-Thalassemia Screening Program in Southeast Iran: A Case Study of Jiroft District

Journal of Health Sciences & Surveillance System
دوره 12، شماره 3، مهر 2024، صفحه 319-326    اصل مقاله (469.95 K)
نوع مقاله: Original Article
شناسه دیجیتال (DOI): 10.30476/jhsss.2023.97455.1707
نویسندگان
Amin Kiani1، 2؛ Elham Ghorbani Aliabadi3، 4؛ Bahareh Kermani5؛ Fatemeh Rezabeigi Davarani6؛ Vahid Rahmanian7؛ Salman Daneshi* 8
1Student Research Committee, School of Nursing and Midwifery, Shiraz University of Medical Sciences, Shiraz, Iran
2Faculty of Nursing and Midwifery, Jiroft University of Medical Science, Jiroft, Iran
3Faculty of Paramedicine, Jiroft University of Medical Science, Jiroft, Iran
4Student Research Committee, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran
5School of Medicine, Jiroft University of Medical Sciences, Jiroft, Iran
6Social Determinants of Health Research Center, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran
7Department of Public Health, Torbat Jam Faculty of Medical Sciences, Torbat Jam, Iran
8Department of Public Health, School of Health, Jiroft University of Medical Sciences, Jiroft, Iran
چکیده
Background: Major β-Thalassemia is the most prevalent singlegene disorder in Iran. Over 2 million beta-thalassemia carriers
and more than 25,000 patients have been identified nationwide. This study aimed to evaluate the Major β-Thalassemia (MBT) screening surveillance system in the Jiroft district, southeast Iran.
Methods: This descriptive study was conducted using the census method and was based on the information recorded in the files of all major thalassemia births (born between 2011 and 2021) in the health centers of Jiroft University of Medical Sciences. A formula was used to calculate the program’s incidence, expected incidence, and success rate. Stata version 14 and Excel software were utilized to analyze the data, and the qualitative data are presented as numerical values and percentages.
Results: During the study periods, 91 patients with betathalassemia Major were born in the population covered by Jiroft University of Medical Sciences. By performing prenatal diagnosis tests in the first weeks of pregnancy and obtaining parental consent for legal abortion, the birth of 422 sick children was prevented. The 11-year incidence of beta-thalassemia major was 5.32 per 10,000, and the expected incidence (if no prevention program was implemented) was 30 per 10,000 live births. The mean success rate of the Major β-Thalassemia surveillance system during the study period was 82.26%, which reached 95.45% in 2021.
Conclusion: The i mplementation of efficient, e ffective h ealth policies influenced by the native culture of the region has resulted in the thalassemia prevention program in Jiroft City being completely effective. The implementation success rate of this program has exceeded 95%. Modeling and adapting these preventive policies can assist in implementing thalassemia prevention programs in other parts of the country and developing countries.

تازه های تحقیق

Amin Kiani (Google Scholar)

Salman Daneshi (Google Scholar)

کلیدواژه‌ها
Beta-thalassemia؛ Incidence؛ Prevention and control؛ Public health surveillance؛ Epidemiology
مراجع
  1. Li C-K. New trend in the epidemiology of thalassaemia. Best Practice & Research Clinical Obstetrics & Gynaecology. 2017; 39:16-26. doi: 1016/j.bpobgyn.2016.10.013; PMID: 27847257.
  2. Karimi M, Emadmarvasti V, Hoseini J, Shoja L. Major causes of hospital admission in beta thalassemia major patients in southern Iran. Iranian journal of pediatrics. 2011;21(4):509. PMID: 23056840; PMCID: PMC3446139.
  3. Bellis G, Parant A. Beta-thalassemia in Mediterranean countries. Findings and outlook. Investigaciones Geográficas. 2021(in press):1-10. doi: 10.14198/INGEO.19079.
  4. De Sanctis V, Kattamis C, Canatan D, Soliman AT, Elsedfy H, Karimi M, et al. β-thalassemia distribution in the old world: an ancient disease seen from a historical standpoint. Mediterranean journal of hematology and infectious diseases. 2017; 9(1). doi: 4084/MJHID.2017.018; PMID: 28293406; PMCID: PMC5333734.
  5. Rezaee AR, Banoei MM, Khalili E, Houshmand M. Beta-Thalassemia in Iran: new insight into the role of genetic admixture and migration. The Scientific World Journal. 2012;2012. doi: 1100/2012/635183; PMID: 23319887; PMCID: PMC3539370.
  6. Saleh-Gohari N, Bazrafshani M. Distribution of β-globin gene mutations in thalassemia minor population of Kerman Province, Iran. Iranian journal of public health. 2010;39(2):69. PMID: 23113009; PMCID: PMC3481756.
  7. Miri M, Tabrizi Namini M, Hadipour Dehshal M, Sadeghian Varnosfaderani F, Ahmadvand A, Yousefi Darestani S, Manshadi M. Thalassemia in Iran in last twenty years: the carrier rates and the births trend. Iranian Journal of Blood and Cancer. 2013;6(1):11-7. URL: http://ijbc.ir/article-1-432-en.html.
  8. Dehbozorgian J, Moghadam M, Daryanoush S, Haghpanah S, Imani fard J, Aramesh A, et al. Distribution of alpha-thalassemia mutations in Iranian population. Hematology. 2015;20(6):359-62. doi: 1179/1607845414Y.0000000227; PMID: 25553732.
  9. Lai K, Huang G, Su L, He Y. The prevalence of thalassemia in mainland China: evidence from epidemiological surveys. Scientific reports. 2017;7(1):920. doi: 1038/s41598-017-00967-2; PMID: 28424478; PMCID: PMC5430438.
  10. Helmi N, Bashir M, Shireen A, Ahmed IM. Thalassemia review: features, dental considerations and management. Electronic physician. 2017;9(3):4003. doi: 19082/4003; PMID: 28461877; PMCID: PMC5407235.
  11. Samavat A, Modell B. Iranian national thalassaemia screening programme. Bmj. 2004;329(7475):1134-7. doi: 1136/bmj.329.7475.1134; PMID: 15539666; PMCID: PMC527686.
  12. Zeinalian M, Samavat A, Fadayee Nobari R, Azin S. Incidence rate of major beta-thalassemia and study of its causes after prevention and control program of thalassemia in Isfahan Province. Scientific Journal of Iranian Blood Transfusion Organization. 2009;6(4):238-47. URL: http://bloodjournal.ir/article-1-365-fa.html.
  13. Akhlaghpoor S. Chorionic villus sampling for beta‐thalassemia: the first report of experience in Iran. Prenatal Diagnosis: Published in Affiliation with the International Society for Prenatal Diagnosis. 2006;26(12):1131-6. doi: 1002/pd.1572; PMID: 17009347.
  14. Khorasani G, Kosaryan M, Vahidshahi K, Shakeri S, Nasehi MM. Results of the national program for prevention of β-thalassemia major in the Iranian Province of Mazandaran. Hemoglobin. 2008;32(3):263-71. doi: 1080/03630260802004269; PMID: 18473242.
  15. Zeinalian M, Moafi A, Fadayi-Nobari R. A study to evaluate the results of pre-marital screening program for beta-thalassemia in Isfahan province, 1997-2010. Scientific Journal of Iran Blood Transfus Organ. 2013;10(1):20-30. URL: http://bloodjournal.ir/article-1-736-fa.html.
  16. Giambona A, Damiani G, Vinciguerra M, Jakil C, Cannata M, Cassara F, et al. Incidence of haemoglobinopathies in Sicily: the impact of screening and prenatal diagnosis. International Journal of Clinical Practice. 2015;69(10):1129-38. doi: 1111/ijcp.12628; PMID: 25727926.
  17. Ladis V, Karagiorga‐Lagana M, Tsatra I, Chouliaras G. Thirty‐year experience in preventing haemoglobinopathies in G reece: achievements and potentials for optimisation. European journal of haematology. 2013;90(4):313-22. doi: 1111/ejh.12076; PMID: 23331260.
  18. Hadipour Dehshal M, Ahmadvand A, Yousefi Darestani S, Manshadi M, Abolghasemi H. Secular trends in the national and provincial births of new thalassemia cases in Iran from 2001 to 2006. Hemoglobin. 2013;37(2):124-37. doi: 3109/03630269.2013.772062; PMID: 23470148.
  19. Hashemieh M, Naghadeh HT, Namini MT, Neamatzadeh H, Dehshal MH. The Iran thalassemia prevention program: success or failure? Iranian journal of pediatric hematology and oncology. 2015;5(3):161. PMID: 26705456; PMCID: PMC4688601.
  20. Ghorbani Aliabadi E, Kiani A. Investigating the causes of Beta Thalassemia after start of prevention program in Jiroft city during 2001-2015. Journal of Jiroft University of Medical Sciences. 2019;6(1):168-77. URL: http://journal.jmu.ac.ir/article-1-222-en.html.
  21. Joulaei H, Shahbazi M, Nazemzadegan B, Rastgar M, Hadibarhaghtalab M, Heydari M, et al. The diminishing trend of β-thalassemia in Southern Iran from 1997 to 2011: the impact of preventive strategies. Hemoglobin. 2014;38(1):19-23. doi: 3109/03630269.2013.858638; PMID: 24274135.
  22. Hadipour Dehshal M, Tabrizi Namini M, Ahmadvand A, Manshadi M, Sadeghian Varnosfaderani F, Abolghasemi H. Evaluation of the national prevention program in Iran, 2007–2009: the accomplishments and challenges with reflections on the path ahead. Hemoglobin. 2014;38(3):179-87. doi: 3109/03630269.2014.893530; PMID: 24669933.
  23. Rezabeigi Davarani E, Mohseni Takaloo F, Vahidnia A, Daneshi S, Rezabeigi Davarani M, Khanjani N, et al. Epidemiological Investigation of a Twenty-Year Major β-Thalassemia Surveillance in Kerman, Iran. Archives of Hygiene Sciences. 2020;9(4):265-74. doi: 52547/ArchHygSci.9.4.265.
  24. Hadipour Dehshal M, Tabrizi Namini M, Hantoushzadeh R, Yousefi Darestani S. β-Thalassemia in Iran: things everyone needs to know about this disease. Hemoglobin. 2019;43(3):166-73. doi: 1080/03630269.2019.1628774; PMID: 31272240.
  25. Miri-Moghaddam E, Naderi M, Izadi S, Mashhadi M. Causes of new cases of major thalassemia in sistan and balouchistan province in South-East of iran. Iranian journal of public health. 2012;41(11):67. PMID: 23304678; PMCID: PMC3521888.
آمار
تعداد مشاهده مقاله: 3
تعداد دریافت فایل اصل مقاله: 3


سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب